IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.
IO Biotech has raised €127M across 1 funding round from 1 investor, most recently a Series B round in Jan 2021. Based in Copenhagen, Denmark; founded 2014; active in Healthtech. Data as of 6 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-01-13 | Series B |
| €127M |
| HBM Healthcare Investments AG |
| View deal → |
